Applicant: ZHI et al. Amendment and Response Serial No.: 10/566,569

: August 21, 2006 Filed

## AMENDMENTS TO THE CLAIMS:

Please amend claims 1-23 and 25-44 as indicated below, add claim 45 and cancel claim 24 without prejudice or disclaimer. This listing of claims replaces all prior versions and listings of claims in the application.

## LISTING OF CLAIMS:

(Currently amended) A compound having the formula: 1.

$$R^{1}$$
 $R^{2}$ 
 $R^{3}$ 
 $R^{3}$ 
 $R^{9}$ 
 $R^{8}$ 
 $R^{8}$ 

wherein:

R<sup>1</sup> is hydrogen, F, Cl, or C<sub>1</sub>-C<sub>3</sub> aliphatic;

R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>4</sub> aliphatic, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, and or C<sub>1</sub>-C<sub>4</sub> heteroaliphatic;

R<sup>3</sup> and R<sup>4</sup>-each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> aliphatic, C<sub>1</sub>- C<sub>4</sub> haloaliphatic, C<sub>1</sub>-C<sub>4</sub> heteroaliphatic, optionally substituted aryl and or heteroaryl;

R<sup>4</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> aliphatic, C<sub>1</sub>- C<sub>4</sub> haloaliphatic, C<sub>1</sub>-C<sub>4</sub> heteroaliphatic, optionally substituted aryl or heteroaryl;

R<sup>5</sup> and R<sup>6</sup> each independently is selected from the group of hydrogen, F, Cl, OR<sup>10</sup>, C<sub>1</sub>-C<sub>4</sub> aliphatic, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, and or C<sub>1</sub>-C<sub>4</sub> heteroaliphatic;

R<sup>7</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> aliphatic, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, and or C<sub>1</sub>-C<sub>4</sub> heteroaliphatic; or

R<sup>7</sup> and R<sup>8</sup> taken together form a carbonyl group;

R<sup>9</sup> is selected from the group of halogen, OR<sup>10</sup>, SR<sup>10</sup>, NR<sup>10</sup>R<sup>11</sup>, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, C<sub>1</sub>-C<sub>4</sub> heteroaliphatic, and or C<sub>1</sub>-C<sub>4</sub> heterohaloaliphatic;

R<sup>10</sup> and R<sup>11</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> aliphatic, phenyl, and or benzyl; and

n = 0 or 1.

2. (Currently amended) A-The compound according to of claim 1, wherein: R<sup>1</sup> is hydrogen, F or Cl;

Applicant: ZHI et al. Serial No.: 10/566,569 **Amendment and Response** 

Filed : August 21, 2006

R<sup>2</sup> is selected from the group of F, Cl, Br, C<sub>1</sub>-C<sub>4</sub> alkyl, and or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and or optionally substituted aryl;

 $R^4$  is  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl or optionally substituted aryl;

R<sup>5</sup> and R<sup>6</sup> each independently is selected from the group of hydrogen, F, Cl, OR<sup>10</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, and or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

R<sup>7</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl, and or  $C_1$ - $C_4$  haloalkyl;

R<sup>9</sup> is selected from the group of halogen, OR<sup>10</sup>, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and or C<sub>1</sub>-C<sub>4</sub> heterohaloalkyl;

R<sup>10</sup> is hydrogen; and

n = 0 or 1.

(Currently amended) A-The compound according to of claim 1, wherein: 3.

R<sup>1</sup> is hydrogen;

R<sup>2</sup> is selected from the group of Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, and or CF<sub>2</sub>Cl;

R<sup>3</sup> and R<sup>4</sup>-each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, and or optionally substituted aryl;

R<sup>4</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl or optionally substituted aryl;

R<sup>5</sup> and R<sup>6</sup> each independently is selected from the group of hydrogen, F, Cl, OR<sup>10</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and or C<sub>1</sub>-C<sub>4</sub> heteroalkyl;

R<sup>7</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> alkyl,  $C_1$ - $C_4$  haloalkyl, and or  $C_1$ - $C_4$  heteroalkyl;

 $R^9$  is selected from the group of halogen,  $OR^{10}$ ,  $C_1$ - $C_4$  haloalkyl,  $C_1$ - $C_4$  heteroalkyl, and or C<sub>1</sub>-C<sub>4</sub> heterohaloalkyl;

R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl; and n = 0 or 1.

(Currently amended) A-The compound according to of claim 1, wherein:

R<sup>1</sup> is hydrogen, F, Cl, or C<sub>1</sub>-C<sub>3</sub> alkyl;

R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, and or C<sub>1</sub>- C<sub>4</sub> heteroalkyl;

Attorney's Docket No.: 3800024-00350 / 1111US Applicant: ZHI et al.

Serial No.: 10/566,569 Amendment and Response : August 21, 2006 Filed

R<sup>3</sup> and R<sup>4</sup>-each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, optionally substituted aryland or heteroaryl;

R<sup>4</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> heteroalkyl, optionally substituted aryl or heteroaryl;

R<sup>5</sup> and R<sup>6</sup> each is hydrogen;

R<sup>7</sup> and R<sup>8</sup> each independently is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> haloalkyl;

R<sup>9</sup> is OR<sup>10</sup>:

R<sup>10</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

and n=0.

5. (Currently amended) A-The compound according to of claim 4, wherein:

R<sup>1</sup> is hydrogen:

R<sup>2</sup> is selected from the group of Cl, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, and or CF<sub>2</sub>Cl;

R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen and C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>4</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl;

R<sup>7</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub> and or CF<sub>2</sub>Cl; and

R<sup>9</sup> is OH.

6. (Currently amended) A-The compound according to of claim 5, wherein:

R<sup>2</sup> is selected from the group of Cl, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub> and or CF<sub>2</sub>Cl;

R<sup>3</sup> and R<sup>4</sup>-each independently is hydrogen or C<sub>1</sub>-C<sub>2</sub> alkyl; and

R<sup>4</sup> is hydrogen or C<sub>1</sub>-C<sub>2</sub> alkyl; and

R<sup>7</sup> and R<sup>8</sup> each independently is selected from the group of hydrogen, CH<sub>3</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub> andor CF<sub>2</sub>Cl.

7. (Currently amended) A-The compound according to of claim 6, wherein:

R<sup>2</sup> is Cl, CH<sub>2</sub>F, CHF<sub>2</sub>, CF<sub>3</sub> or CF<sub>2</sub>Cl;

R<sup>3</sup> and R<sup>4</sup> each is hydrogen or CH<sub>3</sub>; and

R<sup>4</sup> is hydrogen or CH<sub>3</sub>; and

R<sup>7</sup> and R<sup>8</sup> each independently is hydrogen, CH<sub>3</sub>, CF<sub>3</sub> or CF<sub>2</sub>Cl.

(Currently amended) A-The compound according to of claim 7, wherein:

R<sup>2</sup> is Cl, CH<sub>2</sub>F, CHF<sub>2</sub>, or CF<sub>3</sub>;

R<sup>3</sup> and R<sup>4</sup> each is hydrogen or CH<sub>3</sub>; and

R<sup>4</sup> is hydrogen or CH<sub>3</sub>; and

Filed : August 21, 2006

R<sup>7</sup> and R<sup>8</sup> each independently is hydrogen, CH<sub>3</sub> or CF<sub>3</sub>.

9. (Currently amended) A-<u>The</u> compound according to of claim 1, wherein the compound is an androgen receptor modulator.

- 10. (Currently amended) A-The compound according to of claim 1, wherein the compound is an androgen receptor antagonist.
- 11. (Currently amended) A-<u>The</u> compound according of claim 1, wherein the compound is an androgen receptor agonist.
- 12. (Currently amended) A-The compound according of claim 1, wherein the compound is an androgen receptor partial agonist.
- 13. (Currently amended) A-<u>The</u> compound according to of claim 1, wherein the compound is selected from the group of:
- (R) 6 (2 (2, 2, 2-Trifluoroethyl) 1-pyrrolidinyl) 4-trifluoromethyl 2(1H) quinolinone (Compound 101);
- (R) 6-(2-Phenylthiomethyl-1-pyrrolidinyl) 4-trifluoromethyl-2 (1H)-quinolinone (Compound 102);
- (R) 6 (2 (2, 2, 2 Trifluoroethyl) 1 piperidinyl) 4 trifluoromethyl 2(1H) quinolinone (Compound 103);
- (R)-6-(2-Benzyloxymethyl)-1-piperidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 104);
- (R) 6 (2-Diethylaminomethyl-1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound-105);
- 6-(2(R)-Hydroxymethyl-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 106);
- 6-(2(R)-Fluoromethyl-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 107);
- 6-(2(R)-Fluoromethyl-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 108);
- 6-(2(R)-Difluoromethyl-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound **109**);
- 6-(2(R)-Fluoromethyl-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 110);

Applicant: ZHI et al.

Serial No.: 10/566,569

Attorney's Docket No.: 3800024-00350 / 1111US

Amendment and Response

Filed : August 21, 2006

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1<math>H)-quinolinone (Compound **111**);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**112**);

6-(2(R)-(l(S)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**113**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**114**);

6-(2(R)-(2,2,2-Trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 115);

quinolinone (Compound 115);
6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-4(R)-hydroxy-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 116);
6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-4(R)-hydroxy-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 117);
6-(2(R)-(1(S)-Fluoro-2,2,2-trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 118);
6-(2(R)-(1(R)-Fluoro-2,2,2-trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 119);
6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-4(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 120);
6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-4(R)-methyl-1-pyrrolidinyl)-4-

trifluoromethyl-2(1*H*) quinolinone (Compound 121);

6 (2(R) (1(S) Hydroxy 2,2,2-trifluoroethyl) 4(S) methyl-1 pyrrolidinyl) 4-

trifluoromethyl-2(1*H*)-quinolinone (Compound 122);

6 (2(R) (1(R)-Hydroxy-2,2,2 trifluoroethyl) 4 (S)-methyl-1-pyrrolidinyl) 4-

trifluoromethyl-2(1H) quinolinone (Compound-123);

6-(2(R)-(l(R)-Hydroxy-2,2,2-trifluoroethyl)-4(R) methoxy 1 pyrrolidinyl) 4-trifluoromethyl-2(1H) quinolinone (Compound 125);

Applicant : ZHI *et al*.

Serial No. : 10/566,569

Filed : August 21, 2006

Attorney's Docket No.: 3800024-00350 / 1111US

Amendment and Response

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-4(S) methoxy-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 127);

4-Chloro-6-(2(R)-(1(S)-hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-2(1<math>H)-quinolinone (Compound **128**);

4-Chloro-6-(2(R)-(l(R)-hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-2(1H)-quinolinone (Compound 129);

4 Chloro 6 (2(R) (1(S)-hydroxy-2,2,2-trifluoroethyl) 1 pyrrolidinyl) 2(1H)-quinolinone (Compound 130);

4 Chloro-6 (2(R) (1(R) hydroxy-2,2,2-trifluorethyl)-1-pyrrolidinyl) 2(1H)-quinolinone (Compound 131);

6-(2(*R*)-(1(*R*)-Hydroxy-1-methyl-2,2,2-trifluoroethyl)-5(*R*)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **132**);

6-(2(R)-(1(S)-Hydroxy-1-methyl-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**133**);

6-(2(*R*)-(1-Hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)-5(*R*)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **134**);

6-(2(R)-(1(R)-Ethoxy-2,2,2-trifluoroethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 135);

6-(2(R)-(1S)-Hydroxy-2,2,2-trifluoroethyl) 1-pyrrolidinyl) 4-propyl-2(1H)-quinolinone (Compound 137);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-1-pyrrolidinyl)-4-ethyl-2(1H)-quinolinone (Compound 139);

6-(2(R)-Chloromethyl-5-(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 140);

6-(2(R)-Chloromethyl-5-(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 141);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**142**);

Serial No.: 10/566,569 Filed: August 21, 2006

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**143**);

6-(2(R)-(l(S)-Hydroxy-2,2,2-trifluoroethyl)-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1<math>H)-quinolinone (Compound **144**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-<math>2(1H)-quinolinone (Compound **145**);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**146**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**147**);

6 (2(R) (1(R), 2 Dihydroxyethyl) 1 pyrrolidinyl) 4 trifluoromethyl 2(1H)-quinolinone (Compound 148);

6 (2(R)-(1(S), 2-Dihydroxyethyl)-1-pyrrolidinyl)-4 trifluoromethyl-2(1H)-quinolinone (Compound 149);

6-(2(R)-(1(R)-Hydroxybenzyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound**150**);

6-(2(R)-(1(S)-Hydroxybenzyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound**151**);

6-(2(R)-(1(R)-Hydroxybenzyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 152);

6-(2(R)-((2-1,3-Dithianyl)-1(R)-hydroxymethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**153**);

6-(2(R)-((2-1,3-Dithianyl)-1(S)-hydroxymethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**154**);

6-(2(R)-Difluoromethyl-5,5-dimethyl-l-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 155);

6-(2(*R*)-Fluoromethyl-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **156**);

6-(2(*R*)-Hydroxymethyl-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **157**);

6-(2(R)-Hydroxymethyl-1-piperidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 158);

Applicant: ZHI et al. Serial No.: 10/566,569

Filed : August 21, 2006

Attorney's Docket No.: 3800024-00350 / 1111US
Amendment and Response

6 (2(R)-(1(S)-Hydroxyethyl-1-piperidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 159);

6-(2(R) (1(R) Hydroxyethyl-1-piperidinyl) 4-trifluoromethyl-2(1H) quinolinone (Compound 160);

6-(2(R)-(1(S)-Hydroxypentyl-1-piperidinyl)-4-trifluoromethyl-2-(1H)-quinolinone (Compound 162);

6-(2(R)-(1(R)-Hydroxyethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**164**);

6-(2(R)-(1-Hydroxy-1-methylethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**165**);

6-(2(R)-(1(S)-Hydroxy-1-cyclopropylmethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**166**);

6-(2(R)-(1(R)-Hydroxy-1-cyclopropylmethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**167**);

6-(2(R)-(1(S)-Hydroxypropyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 168),

6-(2(R)-(1(R)-Hydroxypropyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 169);

6-(2(R)-(1(R)-Hydroxypropyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 170);

6-(2(R)-(1(S)-Hydroxypropyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 171);

6-(2(R)-(1(R)-Hydroxy-2-methylpropyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**172**);

6-(2(R)-(1(R) Hydroxy-2-acetoxyethyl) 1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 173);

Serial No.: 10/566,569 Filed: August 21, 2006

6-(2(R)-(2-Hydroxyethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 175);

6 (2(R)-(2-Oxoethyl) 1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 176);

6-(2(R)-Acetyloxymethyl-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 177);

6-(2(R)-(1(R)-Chloro-2-hydroxyethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 178);

6-(2(R)-Hydroxymethyl-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 179);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**180**);

6-(2(*R*)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(*R*)-methyl-1-pyrrolidinyl)-4-chloro-difluoromethyl-2(1*H*)-quinolinone (Compound **181**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-chloro-difluoromethyl-2(1*H*)-quinolinone (Compound**182**);

6-(2(*R*)-(1(*S*)-Hydroxy-2,2,2-trifluoroethyl)-5(*S*)-methyl-1-pyrrolidinyl)-4-chloro-difluoromethyl-2(1*H*)-quinolinone (Compound **183**);

6-(2(R)-(2(S)-Hydroxy-3,3,3-trifluoropropyl) 1-pyrrolidinyl) 4-trifluoromethyl-2(1H) quinolinone (Compound 184);

6 (2(R)-(2(R)-hydroxy-3,3,3-trifluoropropyl) 1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 185);

6-(2(R)-Acetyloxymethyl-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound**186**);

6-(2(R)-(2-Hydroxyethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound**187**);

6-(2(R)-(2-Hydroxyethyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 188); or

6-(2(R)-Acetyloxyethyl-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound **189**).

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 190); and

Applicant: ZHI et al. Attorney's Docket No.: 3800024-00350 / 1111US

Serial No.: 10/566,569 **Amendment and Response** Filed : August 21, 2006

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 191).

14. (Currently amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and compound of claim 1. the formula:

$$\begin{array}{c|c}
R^{2} & R^{3} \\
R^{3} \\
R^{9} & R^{8}
\end{array}$$

$$\begin{array}{c|c}
R^{1} & R^{6} \\
R^{9} & R^{8}
\end{array}$$

wherein:

R<sup>1</sup> is hydrogen, F, Cl, or C<sub>1</sub>-C<sub>3</sub>-aliphatic;

R<sup>2</sup> is selected from the group of hydrogen, F, Cl, Br, C<sub>1</sub>-C<sub>4</sub> aliphatic, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, and C<sub>1</sub>-C<sub>4</sub> heteroaliphatic;

R<sup>3</sup> and R<sup>4</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub>-aliphatic, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, C<sub>1</sub>-C<sub>4</sub> heteroaliphatic, optionally substituted aryl and heteroaryl;

R<sup>5</sup> and R<sup>6</sup> each independently is selected from the group of hydrogen, F, Cl, OR 10, C<sub>1</sub>-C<sub>4</sub>-aliphatic, C<sub>1</sub>-C<sub>4</sub>-haloaliphatic, and C<sub>1</sub>-C<sub>4</sub>-heteroaliphatic;

-R<sup>7</sup>-and R<sup>8</sup> each independently is selected from the group of hydrogen, F, Cl, C<sub>1</sub>-C<sub>4</sub> aliphatic, C1-C4 haloaliphatic, and C1-C4 heteroaliphatic; or

R<sup>7</sup>-and R<sup>8</sup>-taken together form a carbonyl group;

R<sup>9</sup> is selected from the group of halogen, OR<sup>10</sup>, SR<sup>10</sup>, NR<sup>10</sup>R<sup>11</sup>, C<sub>1</sub>-C<sub>4</sub> haloaliphatic, C<sub>1</sub>-C<sub>4</sub>-heteroaliphatic, and C<sub>1</sub>-C<sub>4</sub>-heterohaloaliphatic;

R<sup>10</sup> and R<sup>11</sup> each independently is selected from the group of hydrogen, C<sub>1</sub>-C<sub>4</sub> aliphatic, phenyl, and benzyl; and

n = 0 or 1.

- 15. (Currently amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound according to of claim 2.
- 16. (Currently amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound according to of claim 7.

Serial No.: 10/566,569 Filed: August 21, 2006

17. (Currently amended) A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound according to of claim 8.

- 18. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 14, wherein the compound is an androgen receptor modulator.
- 19. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 18, wherein the compound is an androgen receptor antagonist.
- 20. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 18, wherein the compound is an androgen receptor agonist.
- 21. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 18, wherein the compound is an androgen receptor partial agonist.
- 22. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 14, wherein the compound is selected from the group of:
- (R) 6-(2-(2, 2, 2-Trifluoroethyl) 1 pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 101);
- (R) 6 (2-Phenylthiomethyl-1-pyrrolidinyl) 4 trifluoromethyl-2 (1H)-quinolinone (Compound 102);
- (R)-6-(2-(2, 2, 2-Trifluoroethyl) 1-piperidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 103);
- (R) 6-(2-Benzyloxymethyl)-1-piperidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound-104);
- (R) 6 (2 Diethylaminomethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H) quinolinone (Compound 105);
- 6-(2(*R*)-Hydroxymethyl-5(*S*)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **106**);
- 6-(2(R)-Fluoromethyl-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 107);
- 6-(2(R)-Fluoromethyl-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H) quinolinone (Compound 108);
- 6-(2(R)-Difluoromethyl-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 109);

Filed : August 21, 2006

6-(2(*R*)-Fluoromethyl-5(*S*)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **110**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**111**);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**112**);

6-(2(R)-(l(S)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound 113);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**114**);

6-(2(R)-(2,2,2-Trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 115);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-4(R)-hydroxy-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 116);

6-(2(R) (1(R) Hydroxy-2,2,2-trifluoroethyl) 4(R) hydroxy-1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 117);

6-(2(R)-(1(S)-Fluoro-2,2,2-trifluoroethyl) 4(S) fluoro-1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 118);

6 (2(R)-(1(R)-Fluoro-2,2,2 trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 119);

6 (2(R) (1(S) Hydroxy-2,2,2-trifluoroethyl) 4(R) methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H) quinolinone (Compound 120);

6 (2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-4(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 121);

6 (2(R) (1(S)-Hydroxy-2,2,2 trifluoroethyl) 4(S)-methyl-1-pyrrolidinyl) 4 trifluoromethyl-2(1H)-quinolinone (Compound 122);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-4 (S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 123);

- 6 (2(R) (l(R) Hydroxy-2,2,2-trifluoroethyl) 4(R) methoxy-1-pyrrolidinyl) 4-trifluoromethyl-2(1H) quinolinone (Compound 125);

Applicant: ZHI et al. Attorney's Docket No.: 3800024-00350 / 1111US

Serial No.: 10/566,569 Amendment and Response Filed : August 21, 2006

6 (2(R) (1(R) Hydroxy 2,2,2 trifluoroethyl) 4(S) methoxy 1 pyrrolidinyl) 4 trifluoromethyl-2(1H)-quinolinone (Compound 126);

6 (2(R) (1(S) Hydroxy 2,2,2 trifluoroethyl) 4(S) methoxy 1 pyrrolidinyl) 4 trifluoromethyl-2(1H)-quinolinone (Compound 127);

4-Chloro-6-(2(R)-(1(S)-hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-2(1H)-quinolinone (Compound 128);

4-Chloro-6-(2(R)-(1(R)-hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-2(1H)-quinolinone (Compound 129);

4-Chloro-6-(2(R)-(1(S)-hydroxy-2,2,2-trifluoroethyl)-1-pyrrolidinyl)-2(1H)quinolinone (Compound 130);

4-Chloro-6-(2(R) (1(R) hydroxy 2,2,2 trifluorethyl) 1-pyrrolidinyl) 2(1H) quinolinone (Compound 131);

6-(2(R)-(1(R)-Hydroxy-1-methyl-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound 132);

6-(2(R)-(1(S)-Hydroxy-1-methyl-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **133**);

6-(2/R)-(1-Hydroxy-1-trifluoromethyl-2,2,2-trifluoroethyl)-5(R)-methyl-1pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **134**);

6-(2(R)-(1(R) Ethoxy-2,2,2-trifluoroethyl) 1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound-135);

6 (2(R) (1(R) Hydroxy 2,2,2 trifluoroethyl) 1 pyrrolidinyl) 4 propyl 2(1H) quinolinone (Compound 136);

-6-(2(R)-(1S)-Hydroxy-2,2,2-trifluoroethyl)-1-pyrrolidinyl)-4-propyl-2(1H)quinolinone (Compound 137);

6 (2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-1-pyrrolidinyl)-4-ethyl-2(1H)quinolinone (Compound 138);

-6-(2(R) (1(R) Hydroxy-2,2,2-trifluoroethyl) 1-pyrrolidinyl) 4-ethyl-2(1H) quinolinone (Compound 139);

6-(2(R)-Chloromethyl-5-(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 140);

6-(2(R)-Chloromethyl-5-(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 141);

Attorney's Docket No.: 3800024-00350 / 1111US

Amendment and Response

Serial No.: 10/566,569 Filed: August 21, 2006

Applicant: ZHI et al.

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**142**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 143);

6-(2(R)-(l(S)-Hydroxy-2,2,2-trifluoroethyl)-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**144**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**145**);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**146**);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-phenyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**147**);

6-(2(R) (1(R), 2-Dihydroxyethyl) 1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 148);

6 (2(R)-(1(S), 2-Dihydroxyethyl)-1-pyrrolidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 149);

6-(2(R)-(1(R)-Hydroxybenzyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 150);

6-(2(R)-(1(S)-Hydroxybenzyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 151);

6-(2(R)-(1(R)-Hydroxybenzyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1<math>H)-quinolinone (Compound **152**);

6-(2(R)-((2-1,3-Dithianyl)-1(R)-hydroxymethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound**153**);

6-(2(R)-((2-1,3-Dithianyl)-1(S)-hydroxymethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound **154**);

6-(2(*R*)-Difluoromethyl-5,5-dimethyl-l-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **155**);

6-(2(*R*)-Fluoromethyl-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **156**);

6-(2(*R*)-Hydroxymethyl-5,5-dimethyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **157**);

Applicant: ZHI et al. Serial No.: 10/566,569 Amendment and Response

Filed : August 21, 2006

6-(2(R) Hydroxymethyl 1 piperidinyl) 4 trifluoromethyl 2(1H) quinolinone (Compound 158);

6-(2(R) (1(S) Hydroxyethyl 1-piperidinyl) 4-trifluoromethyl-2(1H) quinolinone (Compound-159);

6-(2(R)-(1(R)-Hydroxyethyl-1-piperidinyl) 4-trifluoromethyl-2(1H)-quinolinone (Compound 160);

-6-(2(R)-Trifluoroacetyl-1-piperidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 161);

6-(2(R)-(1(S)-Hydroxypentyl-1-piperidinyl)-4-trifluoromethyl-2-(1H)-quinolinone (Compound 162);

6-(2(R)-(1(R) Hydroxypentyl 1-piperidinyl) 4-trifluoromethyl-2(1H) quinolinone (Compound 163);

6-(2(R)-(1(R)-Hydroxyethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound **164**);

6-(2(R)-(1-Hydroxy-1-methylethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl 2(1H)-quinolinone (Compound 165);

6-(2(R)-(1(S)-Hydroxy-1-cyclopropylmethyl)-5(R)-methyl-1-pyrrolidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 166);

6-(2(R)-(1(R)-Hydroxy-1-cyclopropylmethyl)-5(R)-methyl-1-pyrrolidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 167);

6-(2(R)-(1(S)-Hydroxypropyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 168),

6-(2(R)-(1(R)-Hydroxypropyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 169);

6-(2(R)-(1(R)-Hydroxypropyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound 170);

6-(2(R)-(1(S)-Hydroxypropyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1*H*)-quinolinone (Compound 171);

6-(2(R)-(1(R)-Hydroxy-2-methylpropyl)-5(R)-methyl-1-pyrrolidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 172);

6-(2(R)-(1(R)-Hydroxy-2-acetoxyethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound-173);

Applicant: ZHI et al. Serial No.: 10/566,569 **Amendment and Response** 

Filed : August 21, 2006

6-(2(R)-(1(R)-Hydroxy-2-chloroethyl) 1-pyrrolidinyl) 4-trifluoromethyl-2(1H)quinolinone (Compound 174);

-6-(2(R) (2-Hydroxyethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound-175);

6-(2(R) (2-Oxoethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 176);

6-(2(R)-Acetyloxymethyl-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 177);

6-(2(R)-(1(R)-Chloro-2-hydroxyethyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 178);

6-(2(R)-Hydroxymethyl-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 179);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-6(R)-methyl-1-piperidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 180);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4chlorodifluoromethyl-2(1*H*)-quinolinone (Compound 181);

6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-5(R)-methyl-1-pyrrolidinyl)-4chlorodifluoromethyl-2(1*H*)-quinolinone (Compound 182);

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-5(S)-methyl-1-pyrrolidinyl)-4chlorodifluoromethyl-2(1*H*)-quinolinone (Compound 183);

6-(2(R)-(2(S)-Hydroxy-3,3,3-trifluoropropyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H) quinolinone (Compound 184);

6-(2(R)-(2(R)-hydroxy-3,3,3-trifluoropropyl)-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)-quinolinone (Compound 185);

6-(2(R)-Acetyloxymethyl-6(R)-methyl-1-piperidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 186);

6-(2(R)-(2-Hydroxyethyl)-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 187);

6-(2(R)-(2-Hydroxyethyl)-5(S)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 188); or

6-(2(R)-Acetyloxyethyl-5(R)-methyl-1-pyrrolidinyl)-4-trifluoromethyl-2(1H)quinolinone (Compound 189). [[;]]

Applicant: ZHI et al. Attorney's Docket No.: 3800024-00350 / 1111US Amendment and Response

Serial No.: 10/566,569

Filed : August 21, 2006

6-(2(R)-(1(S)-Hydroxy-2,2,2-trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 190); and 6-(2(R)-(1(R)-Hydroxy-2,2,2-trifluoroethyl)-4(S)-fluoro-1-pyrrolidinyl)-4trifluoromethyl-2(1H)-quinolinone (Compound 191).

- 23. (Currently amended) AThe pharmaceutical composition according to of claim 14, wherein the composition is formulated for oral, topical, intravenous, suppository or parenteral administration.
  - 24. (Cancelled).
- (Currently amended) A method of modulating androgen receptor activity in a 25. mammal, comprising administering to said the mammal a pharmaceutically effective amount of a compound according to of claim 1.
- 26. (Currently amended) A method for modulating a process in a mammal mediated by androgen receptor, comprising administering to said the mammal a pharmaceutically effective amount of a compound according to of claim 1.
- 27. (Currently amended) AThe method according to of claim 25, wherein saidthe mammal has a condition mediated by an androgen receptor.
- 28. (Currently amended) AThe method according to of claim 27, wherein saidthe condition is selected from the group of acne, male-pattern baldness, impotence, sexual dysfunction, wasting diseases, frailty, hirsutism, hypogonadism, prostatic hyperplasia, osteoporosis, cancer cachexia and hormone-dependent cancers.
- 29. (Currently amended) AThe method according to of claim 27, wherein saidthe condition is susceptible to treatment with a therapy selected from the group of male hormone replacement therapy, female androgen replacement therapy and stimulation of hematopoiesis.
- 30. (Currently amended) AThe compound according to of claim 2, wherein the compound is an androgen receptor antagonist.
- 31. (Currently amended) AThe compound according of claim 2, wherein the compound is an androgen receptor agonist.
- 32. (Currently amended) AThe compound according of claim 2, wherein the compound is an androgen receptor partial agonist.

Serial No.: 10/566,569 Filed: August 21, 2006

33. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 15, wherein the compound is an androgen receptor modulator.

- 34. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 33, wherein the compound is an androgen receptor antagonist.
- 35. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 33, wherein the compound is an androgen receptor agonist.
- 36. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 33, wherein the compound is an androgen receptor partial agonist.
- 37. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 16, wherein the compound is an androgen receptor modulator.
- 38. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 37, wherein the compound is an androgen receptor antagonist.
- 39. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 37, wherein the compound is an androgen receptor agonist.
- 40. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 37, wherein the compound is an androgen receptor partial agonist.
- 41. (Currently amended) A<u>The</u> pharmaceutical composition according to of claim 17, wherein the compound is an androgen receptor modulator.
- 42. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 41, wherein the compound is an androgen receptor antagonist.
- 43. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 41, wherein the compound is an androgen receptor agonist.
- 44. (Currently amended) A<u>The</u> pharmaceutical composition according to<u>of</u> claim 41, wherein the compound is an androgen receptor partial agonist.
- 45. (New) A method of treating prostate cancer in a subject, comprising administering to the subject a pharmaceutically effective amount of a compound of claim 1.